ArticleMicrobial cell factories2026
Escherichia coli BL21 adapts its central carbon metabolism to recombinant protein production and oxygen limitation.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-yielding recombinant protein expression systems often face challenges due to the metabolic burden caused by the competition for cellular resources, resulting in reduced growth and, hence, limiting their industrial applicability. Furthermore, industrial recombinant protein production is also affected by the occurrence of oxygen gradients, which is a prevalent issue in large-scale bioreactors. These gradients create a heterogeneous environment in the bioreactor, which affects cell growth and metabolism, having severe consequences on the process performance. Both these factors alter cellular physiology and metabolism, thereby affecting recombinant protein yields. Understanding metabolic adaptations to these stress conditions is crucial for uncovering the underlying cellular mechanisms, which can direct further optimization of the recombinant strains. In this study, we aimed to explore the combined response of the central metabolism of Escherichia coli to metabolic burden and microaerobic conditions. Two recombinant protein-producing E. coli BL21 strains carrying XylS/Pm vectors with low (A2-mCh) and medium plasmid copy numbers (A3-mCh), and producing mCherry protein, were studied by introducing oxygen limitation. Central metabolite pools were analyzed by three targeted LC-MS/MS methods, using the isotope dilution strategy for absolute quantification.
resultsBoth recombinant strains exhibited different levels of metabolic burden, with the strain possessing a higher plasmid copy number showing more pronounced growth retardation and a stronger impact on metabolite pools. Both strains, however, showed a similar response to oxygen limitation, with significant adaptations in the central metabolite pools. The low plasmid copy number strain showed an increase in the concentration of lower glycolytic and tricarboxylic acid cycle metabolites, while the pools of upper glycolytic and pentose phosphate pathways and nucleoside phosphates were mostly unaffected. However, a more extreme response was seen in A3-mCh, where the majority of the metabolite pools were increased. Oxygen limitation caused lower metabolic activity, but the energy charge and redox balance were maintained, and no negative effect was observed on mCherry production rates.
conclusionThis study provides insights into metabolic adaptations in E. coli BL21 recombinant strains, having quite robust mechanisms to maintain intracellular metabolic homeostasis during both internal and external perturbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.